Related references
Note: Only part of the references are listed.Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer
Yuning Liao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress
Hiroki Akiyama et al.
CANCER LETTERS (2019)
Targeting non-oncogene ROS pathway by alantolactone in B cell acute lymphoblastic leukemia cells
Xiaoguang Xu et al.
LIFE SCIENCES (2019)
Homoharringtonine combined with the Heat Shock Protein 90 Inhibitor IPI504 in the Treatment of FLT3-ITD Acute Myeloid Leukemia
Zhaoxing Wu et al.
TRANSLATIONAL ONCOLOGY (2019)
Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia
Taylor M. Weis et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology
Hala Skayneh et al.
GENES (2019)
Hematological malignancies and molecular targeting therapy
Akira Shimada
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
The growing landscape of FLT3 inhibition in AML
Catherine C. Smith
Hematology-American Society of Hematology Education Program (2019)
The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia
Yingchao Fan et al.
HEMATOLOGY (2018)
AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells
Shanshan Pei et al.
CELL STEM CELL (2018)
CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib
Hardikkumar Jetani et al.
LEUKEMIA (2018)
USP10 promotes proliferation and migration and inhibits apoptosis of endometrial stromal cells in endometriosis through activating the Raf-1/MEK/ERK pathway
Qiong Chen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2018)
Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
George M. Burslem et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Characterization of naturally occurring pentacyclic triterpenes as novel inhibitors of deubiquitinating protease USP7 with anticancer activity in vitro
Bo Jing et al.
ACTA PHARMACOLOGICA SINICA (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
FLT3 ligand regulates thymic precursor cells and hematopoietic stem cells through interactions with CXCR4 and the marrow niche
Kirsten M. Williams et al.
EXPERIMENTAL HEMATOLOGY (2017)
ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition
H-Q Ju et al.
LEUKEMIA (2017)
FLT3-ITD and its current role in acute myeloid leukaemia
Francisco Alejandro Lagunas-Rangel et al.
MEDICAL ONCOLOGY (2017)
Inhibition of USP10 induces degradation of oncogenic FLT3
Ellen L. Weisberg et al.
NATURE CHEMICAL BIOLOGY (2017)
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies
J. Kyle Bruner et al.
CANCER RESEARCH (2017)
Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells
Clement Larrue et al.
BLOOD (2016)
The Chemical Molecule B355252 is Neuroprotective in an In Vitro Model of Parkinson's Disease
Nailya S. Gliyazova et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2016)
The Cellular Thermal Shift Assay: A Novel Biophysical Assay for In Situ Drug Target Engagement and Mechanistic Biomarker Studies
Daniel Martinez Molina et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56 (2016)
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Klaus H. Metzeler et al.
BLOOD (2016)
Deubiquitination and Activation of AMPK by USP10
Min Deng et al.
MOLECULAR CELL (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil
Helena Almqvist et al.
NATURE COMMUNICATIONS (2016)
Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice
Samuel J. Taylor et al.
EXPERIMENTAL HEMATOLOGY (2015)
Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer
Mary Ellen Molloy et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl-dependent mechanisms
Wenbin Xu et al.
MOLECULAR MEDICINE REPORTS (2014)
CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors
H. Makishima et al.
LEUKEMIA (2012)
Discovery of N-hydroxy-4-(3-phenylpropanamido) benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer
Jinhong Feng et al.
CANCER BIOLOGY & THERAPY (2011)
Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13
Junli Liu et al.
CELL (2011)
c-Cbl and Cbl-b Ligases Mediate 17-Allylaminodemethoxygeldanamycin-induced Degradation of Autophosphorylated Flt3 Kinase with Internal Tandem Duplication through the Ubiquitin Proteasome Pathway
Gaku Oshikawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation
M. Buchwald et al.
LEUKEMIA (2010)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
Share Paper
